Myovant Sciences, Inc.

NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)This U.S. industry comprises establishments primarily engaged in conducting biotechnology (except nanobiotechnology) research and experimental development. Biotechnology (except nanobiotechnology) research and experimental development involves the study of the use of microorganisms and cellular and biomolecular processes to develop or alter living or non-living materials. This research and development in biotechnology (except nanobiotechnology) may result in development of new biotechnology (except nanobiotechnology) processes or in prototypes of new or genetically-altered products that may be reproduced, utilized, or implemented by various industries. Learn more at the U.S. Census Bureau
Name | Role | Address |
---|---|---|
CORPORATION SERVICE COMPANY | Agent | 222 JEFFERSON BOULEVARD SUITE 200, WARWICK, RI, 02888, USA |
Name | Role | Address |
---|---|---|
DAVID MAREK | CEO/ CHAIRMAN/ DIRECTOR | 2000 SIERRA POINT PARKWAY, 9TH FL BRISBANE, CA 94005 USA |
Name | Role | Address |
---|---|---|
MATTHEW LANG | SECRETARY/ DIRECTOR | 2000 SIERRA POINT PARKWAY, 9TH FL BRISBANE, CA 94005 USA |
Name | Role | Address |
---|---|---|
UNEEK MEHRA | CHIEF FINANCIAL AND BUSINESS OFFICER/ DIRECTOR | 2000 SIERRA POINT PARKWAY, 9TH FL BRISBANE, CA 94005 USA |
Number | Name | File Date |
---|---|---|
202339875470 | Application for Certificate of Withdrawal | 2023-07-28 |
202336508100 | Application for Amended Certificate of Authority | 2023-06-01 |
202336030980 | Annual Report - Amended | 2023-05-24 |
202334832270 | Annual Report | 2023-05-01 |
202216489280 | Annual Report | 2022-04-30 |
This company hasn't received any reviews.
Date of last update: 04 Jun 2025
Sources: Rhode Island Department of State